Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 4/20 | 0.32 |
| ▸ | CTSB | P07858 | 4/20 | 0.32 |
| ▸ | CTSH | P09668 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659314 | 0.83 | CTSK (0.31) | CTSKCTSLCTSBCTSH | |
| SCHEMBL5657935 | 0.82 | DPP4 (0.33) | — | |
| SCHEMBL5658572 | 0.79 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5657974 | 0.77 | CTSK (0.41) | CTSK | |
| SCHEMBL5656723 | 0.75 | GRM3 (0.42) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5660846 | 0.75 | DPP4 (0.42) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL14573070 | 0.75 | CTSK (0.41) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL5659471 | 0.75 | — | — | |
| SCHEMBL5655978 | 0.73 | RECQL (0.38) | CTSSEPHX1CTSLALDH1A1MAPT | |
| SCHEMBL5659416 | 0.73 | POLB (0.37) | CTSSCTSLMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192953-B2 | Antibacterial agents | VERNALIS (OXFORD) LIMITED (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | VERNALIS (OXFORD) LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1567504-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Ltd (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050638-A1 | ANTIBACTERIAL AGENTS | VERNALIS (OXFORD) LTD. (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | HRH2, HCAR3, HCAR2 | CTSK 1622/4885CTSS 635/4885EPHX1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.